Financials Legend Biotech Corporation

Equities

LEGN

US52490G1022

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 18/11/2025 GMT			5-day change	1st Jan Change
29.42 ^USD	-1.01%		-8.15%	-9.59%

11-13	Legend Biotech Corporation Celebrates Official Opening of New Cell Therapy Research and Development Facility in Philadelphia	CI
11-13	RBC Trims Price Target on Legend Biotech to $74 From $75, Keeps Outperform Rating	MT

Projected Income Statement: Legend Biotech Corporation

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026	2027
Net sales ¹	75.68	89.79	117	285.1	627.2	1,038	1,560	2,078
Change	-	18.65%	30.31%	143.7%	119.97%	65.48%	50.34%	33.13%
EBITDA ¹	-220.8	-360.6	-443.2	-392.1	-113.2	-101.6	273.8	634.2
Change	-	-63.35%	-22.9%	11.52%	71.14%	10.23%	369.58%	131.59%
EBIT ¹	-229.2	-373	-455.8	-412.6	-136.5	-153.7	200.2	589.9
Change	-	-62.75%	-22.19%	9.49%	66.91%	-12.61%	230.25%	194.59%
Interest Paid ¹	-4.209	-0.9	-10.8	-21.79	-21.62	-15.92	-21	-5.1
Earnings before Tax (EBT) ¹	-307.6	-386.2	-445.7	-520.1	-158.1	-260.3	168	530
Change	-	-25.55%	-15.41%	-16.69%	69.6%	-64.6%	164.55%	215.46%
Net income ¹	-303.5	-386.2	-446.3	-518.3	-177	-265.9	145	490.5
Change	-	-27.26%	-15.57%	-16.11%	65.84%	-50.22%	154.53%	238.26%
Announcement Date	18/03/21	18/03/22	30/03/23	11/03/24	11/03/25	-	-	-

¹USD in Million

Estimates

Fiscal Period: December	2020 Q4	2021 Q1	2021 Q2	2021 Q3	2021 Q4	2022 Q1	2022 Q2	2022 Q4	2023 Q1	2023 Q2	2023 Q3	2023 Q4	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2025 Q1	2025 Q2	2025 Q3	2025 Q4	2026 Q1	2026 Q2	2026 Q3	2026 Q4	2027 Q1	2027 Q2	2027 Q3
Net sales ¹	40.78	13.68	20.23	16.88	39	40.83	11.97	-	36.34	73.33	96.01	79.46	93.99	186.5	160.2	186.5	195.1	255.1	272.3	319.8	324.5	359.8	388.9	432.4	522.7	522.7	522.7
Change	-	-66.45%	47.88%	-16.56%	130.99%	4.7%	-70.68%	-	-	101.81%	30.93%	-17.24%	18.28%	98.45%	-14.11%	16.43%	4.57%	30.76%	6.77%	17.43%	1.48%	10.88%	8.07%	11.2%	20.88%	0%	0%
EBITDA ¹	-56.42	-76.77	-85.12	-82.13	-114.2	-	-116.1	-	-	-	-53.64	-	-48.59	-36.6	-109.9	52.46	-88.87	-16.03	-27.56	-9.656	-	-	-	-	-	-	-
Change	-	-36.07%	-10.88%	3.52%	-39%	-	-	-	-	-	-	-	-	24.68%	-200.29%	147.73%	-269.41%	81.97%	-71.95%	64.96%	-	-	-	-	-	-	-
EBIT ¹	-59.5	-79.55	-89.26	-86.77	-117.5	-76	-125.5	-	-106.9	-104.3	-56.82	-141	-54.31	-41.97	-115.4	45.66	-94.07	-119.6	-33.44	-29.79	-2.5	21	31.25	56.5	-	-	-
Change	-	-33.69%	-12.2%	2.78%	-35.37%	35.29%	-65.16%	-	-	2.38%	45.53%	-148.14%	61.48%	22.73%	-174.92%	139.58%	-306.01%	-27.12%	72.04%	10.89%	91.61%	940%	48.81%	80.8%	-	-	-
Charge d'intérêts ¹	-	-0.038	-0.052	-	-0.602	-0.994	-1.643	-4.054	-5.113	-5.185	-5.676	-5.82	-5.475	-5.484	-5.504	-5.152	-5.061	-5.222	-	-6	-	-	-	-	-	-	-
Earnings before Tax (EBT) ¹	-57.76	-80.9	-91.58	-124.8	-88.33	-41.09	-193.1	-	-112	-198.8	-62.5	-146.8	-59.79	-17.97	-120.9	40.51	-99.13	-124.8	-39.07	-14.88	-0.2477	17.48	28.31	46.18	94.16	94.71	95.28
Change	-	-40.07%	-13.21%	-36.22%	29.19%	53.49%	-369.91%	-	-	-77.58%	68.57%	-134.92%	59.28%	69.94%	-572.71%	133.51%	-344.7%	-25.89%	68.69%	61.91%	98.34%	7,159.26%	61.91%	63.12%	103.92%	0.58%	0.6%
Net income ¹	-57.83	-80.9	-91.58	-124.8	-88.33	-41.09	-193.2	-	-112.1	-199.1	-62.21	-144.8	-59.79	-18.2	-125.3	26.28	-100.9	-125.4	-39.69	-16.23	-1.108	16.46	27.28	44.98	94.16	94.71	95.28
Change	-	-39.9%	-13.21%	-36.21%	29.19%	53.49%	-370.29%	-	-	-77.63%	68.76%	-132.8%	58.71%	69.57%	-588.73%	120.97%	-483.94%	-24.24%	68.35%	59.11%	93.17%	1,584.79%	65.77%	64.88%	109.33%	0.58%	0.6%
Announcement Date	18/03/21	18/05/21	23/08/21	16/11/21	18/03/22	01/06/22	17/02/23	30/03/23	18/05/23	15/08/23	20/11/23	11/03/24	13/05/24	09/08/24	12/11/24	11/03/25	13/05/25	11/08/25	12/11/25	-	-	-	-	-	-	-	-

¹USD in Million

Estimates

Forecast Balance Sheet: Legend Biotech Corporation

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026	2027
Net Debt ¹	-502	-729	-501	-979	-1,473	-179	-343	-807
Change	-	-45.22%	31.28%	-95.41%	-50.46%	87.85%	-91.62%	-135.28%
Announcement Date	18/03/21	18/03/22	30/03/23	11/03/24	11/03/25	-	-	-

¹USD in Million

Estimates

Cash Flow Forecast: Legend Biotech Corporation

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026	2027
CAPEX ¹	45.75	43.9	35.74	20.08	14.1	18.57	22.15	24.33
Change	-	-4.03%	-18.6%	-43.8%	-29.77%	31.66%	19.28%	9.85%
Free Cash Flow (FCF) ¹	-268.8	-242.4	-237	-413.4	-158.1	-121.5	306.1	567.1
Change	-	9.82%	2.21%	-74.4%	61.74%	23.16%	351.89%	85.26%
Announcement Date	18/03/21	18/03/22	30/03/23	11/03/24	11/03/25	-	-	-

¹USD in Million

Estimates

Forecast Financial Ratios: Legend Biotech Corporation

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026	2027
Profitability
EBITDA Margin (%)	-291.72%	-401.61%	-378.77%	-137.52%	-18.04%	-9.79%	17.55%	30.53%
EBIT Margin (%)	-302.87%	-415.44%	-389.58%	-144.69%	-21.76%	-14.81%	12.83%	28.39%
EBT Margin (%)	-406.5%	-430.11%	-380.94%	-182.41%	-25.21%	-25.08%	10.77%	25.51%
Net margin (%)	-401.02%	-430.12%	-381.48%	-181.75%	-28.22%	-25.62%	9.29%	23.61%
FCF margin (%)	-355.14%	-269.92%	-202.57%	-144.97%	-25.21%	-11.71%	19.61%	27.3%
FCF / Net Income (%)	88.56%	62.76%	53.1%	79.76%	89.33%	45.69%	211.09%	115.61%
Profitability
ROA	-44.31%	-41.99%	-36.43%	-32.6%	-10.06%	-10.36%	9.07%	16.98%
ROE	-284.01%	-102.79%	-59.11%	-51.94%	-15.45%	-18.87%	20.88%	34.52%
Financial Health
Leverage (Debt/EBITDA)	-	-	-	-	-	-	-	-
Debt / Free cash flow	-	-	-	-	-	-	-	-
Capital Intensity
CAPEX / Current Assets (%)	60.45%	48.9%	30.54%	7.04%	2.25%	1.79%	1.42%	1.17%
CAPEX / EBITDA (%)	-20.72%	-12.18%	-8.06%	-5.12%	-12.46%	-18.28%	8.09%	3.84%
CAPEX / FCF (%)	-17.02%	-18.11%	-15.08%	-4.86%	-8.92%	-15.28%	7.24%	4.29%
Items per share
Cash flow per share ¹	-	-	-	-	-0.7877	-0.5848	0.4494	1.01
Change	-	-	-	-	-	25.76%	176.84%	124.73%
Dividend per Share ¹	-	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-	-
Book Value Per Share ¹	2.107	3.055	-	6.88	5.666	4.064	5.999	8.819
Change	-	45%	-	-	-17.65%	-28.28%	47.64%	47%
EPS ¹	-2.56	-2.74	-2.8	-2.94	-0.96	-0.7346	0.5647	1.223
Change	-	-7.03%	-2.19%	-5%	67.35%	23.47%	176.86%	116.6%
Nbr of stocks (in thousands)	132,638	153,946	167,403	181,789	183,451	184,690	184,690	184,690
Announcement Date	18/03/21	18/03/22	30/03/23	11/03/24	11/03/25	-	-	-